Group 1 - The core point of the article is that Lanfeng Biochemical (SZ 002513) held its 28th meeting of the 7th board of directors on October 24, 2025, via telecommunication, where it reviewed the proposal for the third extraordinary shareholders' meeting of 2025 [1] - For the first half of 2025, Lanfeng Biochemical's revenue composition was 77.39% from photovoltaic products and 22.61% from pesticides [1] - As of the time of reporting, Lanfeng Biochemical had a market capitalization of 3.1 billion yuan [1] Group 2 - The article mentions that the Chinese innovative drug sector has sold overseas authorizations worth 80 billion USD this year, highlighting the hot secondary market in biomedicine [1] - A dialogue with Lu Gang, a partner at Chuangdong Investment, indicates that while the secondary market is thriving, the primary market is facing challenges in fundraising [1]

截至发稿，晨光生物市值为70亿元。 每经头条（nbdtoutiao）——中国创新药，今年海外授权已卖出800亿美元！对话创东方投资合伙人卢 刚：生物医药二级市场火热，一级市场为何募资遇冷？ （记者 曾健辉） 每经AI快讯，晨光生物（SZ 300138，收盘价：14.41元）10月24日晚间发布公告称，2025年1-9月计提 减值损失共计2489.61万元，上述事项相应减少公司2025年前三季度利润总额2489.61万元，并相应减少 所有者权益2489.61万元。本次计提资产减值损失未经会计师确认。 2024年1至12月份，晨光生物的营业收入构成为：农副食品加工业（植物提取物）占比100.0%。 ...